BIMT-17, commonly known as Flibanserin, is a new pharmaceutical drug developed by Boehringer Ingelheim. Flibanserin is suspected of having a positive effect on women who suffer from decreased desire for sexual activity. The drug is, among other things, a dopamine D4 receptor partial agonist that was originally designed to function as an anti-depressant.

There is currently very little publicly available data regarding Flibanserin. However, on the 16th of November in 2009, Flibanserin’s producer, Boehringer Ingelheim, had reported that Flibanserin promoted the desire for sexual activity and raised the number of ‘sexually satisfying’ moments in the lives of women who were plagued with irregularly low libido, in late-stage trials.

Phase III studies were conducted with over two thousand pre-menopausal females who were affected by HSDD: Hypoactive Sexual Desire Disorder. Women who were under the effects of Flibanserin claimed to have had sexually satisfying events more often than before using the drug. In fact, a raise from 2.8 to 4.5 times a month was shown by the results. On the other hand, women who were under the effects of a placebo claimed that a raise to approximately 3.7 times per month. Current information estimates that Flibanserin must be taken for up to twenty eight days before an effect appears.

The last reports on Flibanserin, back in November of 2009, stated that the Phase III clinial trials for the drug are ‘assessing safety and efficacy’ in both pre- and post-menopausal females.

Scientific Reference Information:
IUPAC Designation: 1-[2-[4-(3-trifluoromethyl phenyl) piperazin-1-yl] ethyl] benzimidazol- [1H]-2-one
CAS Number: 167933-07-5
PubChem: 6918248
Chemical Forumla: C20H21F3N4O

One Response to “What is Flibanserin?”